|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multimodality approach for locally advanced esophageal cancer显示文摘Carcinoma of the esophagus is an aggressive and lethal malignancy with an increasing incidence worldwide.Incidence rates vary internationally,with the highest rates found in Southern and Eastern Africa and Eastern Asia,and the lowest in Western and Middle Africa and Central America.Patients with locally advanced disease face a poor prognosis,with 5-year survival rates ranging from 15%-34%.Recent clinical trials have evaluated different strategies for management of locoregional cancer;however,because of stage migration and changes in disease epidemiology,applying these trials to clinical practice has become a daunting task.We searched Medline and conference abstracts for randomized studies published in the last 3 decades.We restricted our search to articles published in English.Neoadjuvant chemoradiotherapy followed by surgical resection is an accepted standard of care in the United States.Esophagectomy remains an essential component of treatment and can lead to improved overall survival,especially when performed at high volume institutions.The role of adjuvant chemotherapy following curative resection is still unclear.External beam radiation therapy alone is considered palliative and is typically reserved for patients with a poor performance status. | Khaldoun Almhanna Jonathan R Strosberg | 2012 | World Journal of Gastroenterology2012，18，40： | 12 |
| 2 | Metastatic type 1 gastric carcinoid:A real threat or just a myth?显示文摘AIM:To describe disease characteristics and treatment modalities in a group of rare patients with metastatic gastric carcinoid type 1(GCA1).METHODS:Information on clinical,biochemical,radiological,histopathological findings,the extent of the disease,as well as the use of different therapeutic modalities and the long-term outcome were recorded.Patients’data were assessed at presentation,and thereafter at 6 to 12 monthly intervals both clinically and biochemically,but also endoscopically and histopathologically.Patients were evaluated for the presence of specific symptoms;the presence of autoimmune disorders and the presence of other gastrointestinal malignancies in other family members were also recorded.The evaluation of response to treatment was defined using established WHO criteria.RESULTS:We studied twenty consecutive patients with a mean age of 55.1 years.The mean follow-up period was 83 mo.Twelve patients had regional lymph node metastases and 8 patients had liver metastases.The primary tumor mean diameter was 20.13±10.83mm(mean±SD).The mean Ki-67 index was 6.8%±11.2%.All but one patient underwent endoscopic or surgical excision of the tumor.The disease was stable in all but 3 patients who had progressive liver disease.All patients remained alive during the follow-up period.CONCLUSION:Metastatic GCA1 carries a good overall prognosis,being related to a tumor size of≥1 cm,an elevated Ki-67 index and high serum gastrin levels. | Simona Grozinsky-Glasberg Dimitrios Thomas Jonathan R Strosberg Ulrich-Frank Pape Stephan Felder Apostolos V Tsolakis Krystallenia I Alexandraki Merav Fraenkel Leonard Saiegh Petachia Reissman Gregory Kaltsas David J Gross | 2013 | World Journal of Gastroenterology2013，19，46： | 11 |
| 3 | Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors显示文摘Somatostatin analogs were initially developed for the control of hormonal syndromes associated with neuro-endocrine tumors (NETs). In recent years, accumul ating data has supported their role as antiproliferative agents, capable of stabilizing tumor growth in patients with metastatic neuroendocrine malignancies, including carci-noid and pancreatic endocrine tumors. A phase Ⅲ, ran-domized, placebo-controlled trial has now demonstrated that octreotide long-acting repeatable (LAR) 30 mg can significantly prolong time to tumor progression among patients with metastatic midgut NETs regardless of functional status, chromogranin A level or age. In addition to signif icantly lengthening time to tumor pro-gression in the overall study population, subset analysis suggests that patients with low tumor burden are most likely to experience disease stabilization with octreotide LAR 30 mg, supporting the early use of octreotide LAR in patients with metastatic disease. Further research efforts are underway to evaluate the use of somatostatin analogs as antiproliferative agents in other types of gastroenteropancreatic-NETs. Ongoing studies are also evaluating novel somatostatin analogs and somatostatin analogs in combination with other anti-tumor therapies. | Jonathan Strosberg Larry Kvols | 2010 | World Journal of Gastroenterology2010，16，24： | 10 |
| 4 | Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR:A systematic literature review显示文摘AIM:To review literature on efficacy and safety of octreotide-long-acting repeatable(LAR)used at doses higher than the Food and Drug Administration(FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors(NETs).METHODS:We searched Pub Med and Cochrane Library from 1998-2012,5 conferences(American Society of Clinical Oncology,Endocrine Society,European Neuroendocrine Tumor Society,European Society for Medical Oncology,North American Neuroendocrine Tumor Society)from 2000-2013 using Me SH and keyterms including neuroendocrine tumors,carcinoid tumor,carcinoma,neuroendocrine,and octreotide.Bibliographies of accepted articles were also searched.Two reviewers reviewed titles,abstracts,and full-length articles.Studies that reported data on efficacy and safety of≥30 mg/mo octreotide-LAR for NETs in human subjects,published in any language were included in the review.RESULTS:The search identified 1086 publications,of which 238 underwent full-text review(20 were translated into English);17 were included in the review.Studies varied in designs,subjects,octreotide-LAR regimens,and definition of outcomes.Eleven studies reported use of higher doses to control symptoms and tumor progression,although symptom severity and formal quality-of-life analysis were not quantitatively measured.Ten studies reported efficacy,describing 260 subjects with doses ranging from 40 mg/mo or 30 mg/3 wk up to 120 mg/mo.Eight studies reported expert clinical opinion that supported dose escalation of octreotide-LAR up to 60 mg/mo for symptom control and suggested increased doses may be effective at preventing tumor progression.Eight studies reported safety;there was no evidence of increased toxicity associated with doses of octreotide-LAR>30 mg/mo.CONCLUSION:As reported in this review,octreotide-LAR at doses>30 mg/mo is being prescribed for symptom and tumor control in NET patients.Furthermore,expert clinical opinion provided support for escalation of somatostatin analogs for refractory hormonal symptoms. | Michael S Broder David Beenhouwer Jonathan R Strosberg Maureen P Neary Dasha Cherepanov | 2015 | World Journal of Gastroenterology2015，21，6： | 8 |
| 5 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 6 | β-adrenergic receptor-dependent and-independent stimulation of adenylate cyclase is impaired during severe sepsis in humans 显示文摘 | Bernardin G Strosberg AD Bernard A | 1998 | Intensive Care Med1998，24，8： | 1 |
| 7 | Leptin and leptin receptor polymorphisms are associated with in- creased risk and poor prognosis of breast carcinoma 显示文摘 | Snoussi K Strosberg AD Bouaouina N | 2006 | BMC Cancer2006，6，： | 1 |
| 8 | Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neurendocrine tumors显示文摘 | Strosberg JR Cheema A Weber J | 2011 | J Clin Oncol2011，29，22： | 1 |
| 9 | Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut显示文摘 | Strosberg J Gardner N Kvols L | | 0，，04： | 1 |
| 10 | Prognostic Validity of a Novel American Joint Committee on Cancer Staging Clas- sification for Pancreatic Neuroendocrine Tumors 显示文摘 | Strosberg JR Cheema A Weber J | 2011 | J Clin Oncol2011，29，22： | 1 |
| 11 | The NANETS consensus guidelines for the diagnosis and management of gas- trointestinal neuroendocrine tumors ( nets ): well-differentiated nets of the distal colon and rectum 显示文摘 | Anthony LB Strosberg JR Klimstra DS | 2010 | Pancreas2010，39，6： | 1 |
| 12 | Update on the management of unusual neu- roendocrine tumors: pheochromocytoma and paraganglio- ma, medullary thyroid cancer and adrenocortical carcino- ma显示文摘 | Strosberg J R | 2013 | Semiu Oucol2013，40，1： | 1 |
| 13 | Management of adrenocortical carcinoma显示文摘 | Strosberg J R Hammer G D Doherty G M | 2009 | J Natl Compr Canc Netw2009，7，7： | 1 |
| 14 | Genetic variation in pro-inflammatory cytokines(interleukin-1 beta,interleukin-1 alpha and interleukin-6 associated with the aggressive forms,survival,and relapse prediction of breast carcinoma显示文摘 | Snoussi K Strosberg AD Ben AS | 2005 | Eur Cytokine Netw2005，16，4： | 1 |
| 15 | A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract 显示文摘 | Strosberg JR Cheema A Kvols LK | 2011 | Cancer Control2011，18，2： | 1 |
| 16 | Targeting Akt protein kinase in gastric cancer 显示文摘 | Almhanna K Strosberg J Malafa M | 2011 | Anticancer Res2011，31，12： | 1 |
| 17 | Biotechnology of beta-adrenergic receptors显示文摘 | Strosberg AD | | 0，，： | 1 |
| 18 | United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment显示文摘AIM: To assess advanced neuroendocrine tumor (NET) treatment patterns and resource utilization by tumor progression stage and tumor site in the United States. METHODS: United States Physicians meeting eligibility criteria were provided with online data extraction forms to collect patient chart data on recent NET patients. Resource utilization and treatment pattern data were collected over a baseline period (after diagnosis and before tumor progression), as well as initial and secondary progression periods, with progression defined according to measureable radiographic evidence of tumor progression. Resource categories used in the analysis include: Treatments (e.g. , surgery, chemotherapy, radiotherapy, targeted therapies), hospitalizations and physician visits, diagnostic tests (biomarkers, imaging, laboratory tests). Comparisons between categories of resource utilization and tumor progression status were examined using univariate (by tumor site) and multivariate analyses (across all tumor sites). RESULTS: Fifty-five physicians were included in the study and completed online data extraction forms using the charts of 110 patients. The physician sample showed a relatively even distribution for those affiliated with academic versus community hospitals (46% vs 55%). Forty (36.3%) patients were reported to have pancreatic NET (pNET), while 70 (63.6%) patients had gastrointestinal tract (GI)/Lung as the primary NET site. Univariate analysis showed the proportion of patients hospitalized increased from 32.7% during baseline to 42.1% in the progression stages. While surgeries were performed at similar proportions overall at baseline and progression, pNET patients, were more likely than GI/Lung NET patients to have undergone surgery during the baseline (33.3% vs 25.0%) and any progression periods (26.7% vs 23.4%). While peptide-receptor radionuclide and targeted therapy utilization was low across NET types and tumor stages, GI/Lung types exhibited greater utilization of these technologies compared to pNET. Chemotherapy utilization was also greater among GI/Lung types. Multivariate analysis results demonstrated that patients in first progression period were over 3 times more likely to receive chemotherapy when compared to baseline (odds ratio: 3.31; 95%CI: 1.46-7.48, P=0.0041). Further, progression was associated with a greater likelihood of having a study physician visit [relative risk (RR): 1.54; 95%CI: 1.10-2.17, P=0.0117], and an increased frequency of other physician visits (RR: 1.84; 95%CI: 1.10-3.10, P=0.0211). CONCLUSION: Resource utilization in advanced NET in the United States is significant overall and data suggests progression has an impact on resource utilization regardless of NET tumor site. | Jonathan Strosberg Roman Casciano Lee Stern Rohan Parikh Maruit Chulikavit Jacob Willet Zhimei Liu Xufang Wang Krzysztof J Grzegorzewski | 2013 | World Journal of Gastroenterology2013，19，15： | 1 |
| 19 | Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases显示文摘 | Strosberg J Nasir A Cragnn J | 2007 | Gynecol Oncol2007，106，1： | 1 |
| 20 | The NANETS consensus guidelines for the diagnosis and management of poorly differentiated(high-grade) extrapulmonary neuroendocrine carcinomas显示文摘 | Strosberg JR Coppola D Klimstra DS | 2010 | Pancreas2010，39，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员